Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Wrong potency or content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.

992 FDA drug recalls with this cause, newest first.

These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.

Class II · Moderate risk

Sensorcaine-MPF

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-468-01 D-0129-2023
Class II · Moderate risk

Sensorcaine

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-463-01 D-0128-2023
Class II · Moderate risk

Sensorcaine

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-461-01 D-0127-2023